Choung Rok Seon, Rubio-Tapia Alberto, Lahr Brian D, Kyle Robert A, Camilleri Michael J, Locke G Richard, Talley Nicholas J, Murray Joseph A
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1937-43. doi: 10.1016/j.cgh.2015.05.014. Epub 2015 May 16.
BACKGROUND & AIMS: Celiac disease has been linked to irritable bowel syndrome (IBS)-like symptoms in outpatient clinics. Guidelines recommend that all patients with IBS-like symptoms undergo serologic testing for celiac disease, but there is controversy over whether celiac disease is more prevalent in populations with IBS-like symptoms. We aimed to determine whether positive results from serologic tests for celiac disease are associated with IBS and other functional gastrointestinal disorders (FGIDs) in a large U.S. white population.
Validated, self-report bowel disease questionnaires (BDQs) were sent to randomly selected cohorts of Olmsted County, Minnesota residents. In separate protocols, serum samples were collected from more than 47,000 Olmsted County residents without a prior diagnosis of celiac disease; we performed serologic tests for celiac disease on stored serum samples from residents who completed the BDQ. Logistic regression was used to test for the association between serologic markers of celiac disease (positive vs negative) and individual FGIDs.
A total of 3202 subjects completed the BDQ and had serum available for testing. IBS was identified in 13.6% of these subjects (95% confidence interval [CI], 12.4%-14.8%), and any gastrointestinal symptom occurred in 55.2% (95% CI, 53.5%-56.9%). The prevalence of celiac disease on the basis of serologic markers was 1.0% (95% CI, 0.7%-1.4%). IBS was less prevalent in patients with celiac disease (3%) than patients without celiac disease (14%), although the difference was not statistically significant (odds ratio, 0.2; 95% CI, 0.03-1.5). Abdominal pain, constipation, weight loss, and dyspepsia were the most frequent symptom groups in subjects who were seropositive for celiac disease, but none of the gastrointestinal symptoms or disorders were significantly associated with celiac disease serology.
Symptoms indicative of FGIDs and seropositive celiac disease are relatively common in a U.S. white community. Testing for celiac disease in patients with IBS in the community may not have a significantly increased yield over population-based screening in the United States.
在门诊中,乳糜泻与肠易激综合征(IBS)样症状有关。指南建议,所有有IBS样症状的患者都应接受乳糜泻的血清学检测,但对于IBS样症状人群中乳糜泻是否更普遍存在争议。我们旨在确定在美国一大群白人中,乳糜泻血清学检测阳性结果是否与IBS及其他功能性胃肠疾病(FGIDs)相关。
向明尼苏达州奥姆斯特德县居民的随机选定队列发送经过验证的自报肠道疾病问卷(BDQs)。在不同的方案中,从47000多名此前未被诊断为乳糜泻的奥姆斯特德县居民中采集血清样本;我们对完成BDQ的居民的储存血清样本进行了乳糜泻的血清学检测。采用逻辑回归分析来检验乳糜泻血清学标志物(阳性与阴性)与个体FGIDs之间的关联。
共有3202名受试者完成了BDQ并提供了可用于检测的血清。这些受试者中13.6%被诊断为IBS(95%置信区间[CI],12.4%-14.8%),55.2%出现了任何胃肠道症状(95%CI,53.5%-56.9%)。基于血清学标志物的乳糜泻患病率为1.0%(95%CI,0.7%-1.4%)。乳糜泻患者中IBS的患病率(3%)低于无乳糜泻患者(14%),尽管差异无统计学意义(比值比,0.2;95%CI,0.03-1.5)。腹痛、便秘、体重减轻和消化不良是乳糜泻血清学阳性受试者中最常见的症状组,但没有任何胃肠道症状或疾病与乳糜泻血清学显著相关。
在美国白人社区中,提示FGIDs的症状和乳糜泻血清学阳性相对常见。在社区中对IBS患者进行乳糜泻检测,其检出率可能不会比美国基于人群的筛查有显著提高。